• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Virta Adds Prediabetes and Obesity Reversal to Services

by Jasmine Pennic 10/07/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Virta Expands Offerings to Treat New Group of Chronic Illnesses

What You Should Know:

– Virta is expanding its suite of treatment options to include prediabetes reversal, obesity reversal, and type 2 diabetes management.

– By making this crucial expansion, Virta can scale its treatment to support the tens of millions of additional patients with prediabetes and obesity, as provide an on-ramp to reversal for those with T2D that aren’t yet ready to reverse. 


Virta Health, the leader in type 2 diabetes reversal, today introduced the addition of new services including prediabetes reversal, obesity treatment, and provider-led management for type 2 diabetes. The expansion provides payers and covered beneficiaries a single, full-service virtual clinic that offers industry-leading outcomes for the most critical needs in metabolic health.

Virta’s fully-virtual, high-touch model demonstrates hope for change, and stands in stark contrast to approaches that only slow the diabetes downward spiral, as opposed to reversing it. Virta provides individualized guidance from medical providers and behavioral specialists, whenever and wherever it is needed. Patients interact with their dedicated clinical team often multiple times per day. This novel telehealth approach—called Continuous Remote Care—ensures successful adoption of Virta’s individualized medical nutrition therapies and long-lasting results.


Why It Matters

Nearly half of adults in the United States suffer from obesity, prediabetes, or type 2 diabetes. Thirty people die per hour of diabetes-related causes. The economic burden continues to grow, and people with diabetes incur nearly $17,000 in medical expenses per year. They are also at high risk for severe illness from COVID-19, and risk of dying from the disease is twice as high compared to those without diabetes.

Obesity and prediabetes patients will benefit from the same treatment that delivers the sustained type 2 diabetes reversal outcomes in Virta’s clinical trial and commercially-covered population. Patients receiving type 2 diabetes management will receive support from a provider-led care team, with personalized guidance and an option for a seamless transition to Virta’s reversal treatment. All patients will receive individualized care via Virta’s provider-led Continuous Remote Care platform.

Virta Type 2 Diabetes Reversal Results

Virta’s results in type 2 diabetes reversal have fueled continued triple-digit year-over-year growth for the company while creating strong demand to bring Virta’s evidence-based approach to other metabolic conditions. In Virta’s peer-reviewed clinical trial results, 60% of people at one-year reverse type 2 diabetes, and 94% reduce insulin use or eliminate it altogether.

Additionally, patients completing one year of the Virta Treatment experience 14% weight loss. This figure exceeds the goal of the National Diabetes Prevention Program and the FDA benchmark for weight loss drugs by nearly 200%.

“This expansion provides our commercial partners and patients with the transformational outcomes they’ve come to expect from Virta, but don’t receive from other solutions on the market,” said Sami Inkinen, CEO & co-founder of Virta Health. “We can now meet every patient wherever they are on their metabolic health journey, while uniquely offering a path to reversing their chronic disease.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Clinical Trial, diabetes, Diabetes Management, Diabetes Management Platform, Diabetes Prevention Platform, Diabetes Reversal, FDA, insulin, model, Obesity, Partners, Payers, risk, Type 2 Diabetes, Virta Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |